Baricitinib Continuation Rate High in Real-World Practice medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
email article
Stereotactic body radiotherapy (SBRT) proved safe for treating cancer patients with multiple metastases, according to a phase I trial.
In the NRG-BR001 trial, standard doses of SBRT were safe in 35 patients with oligometastatic breast, prostate, and non-small cell lung cancer (NSCLC) with a median of three or four metastases, or two within proximity to each other, reported Steve Chmura, MD, PhD, of University of Chicago Medicine, and colleagues.
Also, there were no protocol-defined dose-limiting toxicities in these patients at 180 days after the initiation of therapy, they stated in
However, the authors noted that a number of patients experienced late grade 3 adverse events (AEs), most likely related to the protocol therapy, which demonstrated the need for long-term follow-up with these patients.